Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NRP-1 siRNA
- Development stage
- Preclinical
- Lead developer
- Environ
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous, Intravenous, Intratumoral, Inhalation, Intralesional
01
Overview
NRP-1 siRNA is a small interfering RNA (siRNA) therapeutic candidate designed to silence the expression of Neuropilin-1 (NRP-1), specifically the proteoglycan form (PG-NRP1), in metastatic carcinoma-associated fibroblasts (mCAFs). Developed by Environ, this agent aims to modulate the tumor microenvironment by reversing the activated phenotype of CAFs, which are known to promote cancer progression and metastasis. In preclinical studies, knockdown of NRP-1 in mCAFs led to a reduction in activation markers such as alpha-smooth muscle actin (a-SMA), Tenascin C, and Fibronectin, and inhibited the migration and invasion of cancer cells in various solid tumors, including prostate, breast, colorectal, and pancreatic cancers. The siRNA was used to validate NRP-1 as a target for a novel CAF-therapy, leading to the engineering of a small molecule inhibitor for the same pathway.
- Other names
- Neuropilin-1 siRNANeuropilin1 siRNANeuropilin 1 siRNAPG-NRP1 siRNAPG-NRP-1 siRNAPG-NRP 1 siRNA
02
Targets
NRP1 (Neuropilin-1)
Beyond the preview
Go deeper on NRP-1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NRP-1 siRNA.